The agency is authorizing extending the time undiluted, thawed vaccine vials can be stored in the refrigerator to one month.
FDA announced on May 19, 2021 that it was authorizing extending the time undiluted, thawed Pfizer/BioNTech COVID-19 vaccine vials can be stored in the refrigerator at 2 0C to 8 0C to one month. The change comes after the agency reviewed data submitted by Pfizer that demonstrated vials of the vaccine remained stable for up to one month at refrigerator temperatures. Thawed, undiluted vaccine vials were previously stored in the refrigerator for up to five days. The European Medicines Agency also approved the extended refrigeration time period.
“Making COVID-19 vaccines widely available is key to getting people vaccinated and bringing the pandemic to an end. Pfizer Inc. submitted data to the FDA to support storage of undiluted, thawed vials of its COVID-19 vaccine for up to one month at refrigerator temperatures. This change should make this vaccine more widely available to the American public by facilitating the ability of vaccine providers, such as community doctors’ offices, to receive, store, and administer the vaccine,” said the Center for Biologics Evaluation and Research, Peter Marks, MD, PhD, in a press release.
Source: FDA
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
2 Commerce Drive
Cranbury, NJ 08512